Lexicon Pharmaceuticals LXRX 67.84% shares plummeted after the company received a written notice from Sanofi SNY 2.49% terminating the agreement for the development and commercialization of the company’s Diabetes drug candidate Sotagliflozin.
Lexicon Pharmaceuticals shares were trading were trading down 47.45% at $2.99 in Monday’s pre-market session. The stock has a 52-week high of $12.95 and a 52-week low of $4.25.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.